Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a Phase 1b randomized, placebo‐controlled, double‐blind, crossover study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL747 in subjects with Alzheimer's disease (AD)
Epistemonikos ID: 6ae2efc4309487e913233af1861c18ffd94e8756
First added on: May 21, 2024